These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9859967)

  • 61. Going social: Success in online recruitment of men who have sex with men for prevention HIV vaccine research.
    Buckingham L; Becher J; Voytek CD; Fiore D; Dunbar D; Davis-Vogel A; Metzger DS; Frank I
    Vaccine; 2017 Jun; 35(27):3498-3505. PubMed ID: 28526330
    [TBL] [Abstract][Full Text] [Related]  

  • 62. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
    Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
    Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults.
    Durier C; Launay O; Meiffrédy V; Saïdi Y; Salmon D; Lévy Y; Guillet JG; Pialoux G; Aboulker JP
    AIDS; 2006 Apr; 20(7):1039-49. PubMed ID: 16603857
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand.
    Newman PA; Roungprakhon S; Tepjan S; Yim S
    Vaccine; 2010 Jan; 28(4):958-64. PubMed ID: 19925897
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Receiving a positive HIV test result: the experience of patients in Europe.
    Schrooten W; Dreezen C; Fleerackers Y; Andraghetti R; Finazzi R; Caldeira L; Platteau T; Colebunders R;
    HIV Med; 2001 Oct; 2(4):250-4. PubMed ID: 11737405
    [TBL] [Abstract][Full Text] [Related]  

  • 66. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
    Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
    Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania.
    Tarimo EA; Thorson A; Kohi TW; Bakari M; Sandstrom E; Mhalu F; Kulane A
    BMC Infect Dis; 2011 Oct; 11():283. PubMed ID: 22023776
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Postface: Meaning of the Experiment and Implications of the Experience.
    Le Marcis F
    J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S69-S73. PubMed ID: 30222707
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts.
    Gilbert PB
    Stat Med; 2010 May; 29(10):1061-71. PubMed ID: 20419758
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.
    Stevens W; Kamali A; Karita E; Anzala O; Sanders EJ; Jaoko W; Kaleebu P; Mulenga J; Dally L; Fast P; Gilmour J; Farah B; Birungi J; Hughes P; Manigart O; Stevens G; Yates S; Thomson H; von Lieven A; Krebs M; Price MA; Stoll-Johnson L; Ketter N
    PLoS One; 2008 Apr; 3(4):e2043. PubMed ID: 18446196
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Experiences in recruiting volunteers through community based initiatives in phase-1 vaccine trials in India.
    Sahay S; Kumar M; Srikrishnan AK; Ramanathan V; Mehendale S
    Hum Vaccin Immunother; 2014; 10(2):485-91. PubMed ID: 24141176
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Why did I participate in an HIV vaccine study? Experiences of participation in the first phase II HIV vaccine trial in Mozambique: An ancillary study using a mixed-method approach.
    Ubisse Capitine IP; Manhiça ÁM; Tembe Júnior P; Ramgi PM; Chicumbe S; Kroidl A; Fischer MR; De Schacht C
    Vaccine X; 2024 Aug; 19():100510. PubMed ID: 39021617
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characteristics of volunteer participants in phase I HIV vaccine trials.
    Crumbo CL; Rybczyk GK; Wagner LJ
    J Assoc Nurses AIDS Care; 1997; 8(5):59-65. PubMed ID: 9298470
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Conceptual framework for behavioral and social science in HIV vaccine clinical research.
    Lau CY; Swann EM; Singh S; Kafaar Z; Meissner HI; Stansbury JP
    Vaccine; 2011 Oct; 29(44):7794-800. PubMed ID: 21821083
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Participant retention in clinical trials of candidate HIV vaccines.
    de Bruyn G; Hudgens MG; Sullivan PS; Duerr AC
    J Acquir Immune Defic Syndr; 2005 Aug; 39(4):499-501. PubMed ID: 16010176
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Exceptional Risk: Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.
    Cottingham MD; Kalbaugh JM; Swezey T; Fisher JA
    J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1(Suppl 1):S30-S36. PubMed ID: 30222703
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy.
    Nurgat ZA; Craig W; Campbell NC; Bissett JD; Cassidy J; Nicolson MC
    Br J Cancer; 2005 Mar; 92(6):1001-5. PubMed ID: 15770219
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Malicious whites, greedy women, and virtuous volunteers: negotiating social relations through clinical trial narratives in South Africa.
    Saethre E; Stadler J
    Med Anthropol Q; 2013 Mar; 27(1):103-20. PubMed ID: 23674325
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recruitment and Engagement in Preventive Clinical Trials: Interdependencies and Mediation.
    Ollivier-Yaniv C
    J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S3-S7. PubMed ID: 30222699
    [TBL] [Abstract][Full Text] [Related]  

  • 80. When a serious adverse event in research occurs, how do other volunteers react?
    Kennedy CE; Kass N; Myers RK; Fuchs EJ; Flexner C
    J Empir Res Hum Res Ethics; 2011 Jun; 6(2):47-56. PubMed ID: 21680976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.